<DOC>
	<DOCNO>NCT02998840</DOCNO>
	<brief_summary>The purpose study evaluate compare efficacy B244 treat patient hypertension .</brief_summary>
	<brief_title>A Prospective Study B244 Delivered Topical Spray Determine Safety Efficacy Subjects With Elevated Blood Pressure</brief_title>
	<detailed_description>This Prospective , Vehicle Controlled , Double Blinded , Multicenter , Randomized Phase II trial , compare effect twice daily B244 application 4 week vs vehicle application BP inflammatory biomarkers .</detailed_description>
	<mesh_term>Prehypertension</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Male female subject ≥18 year age In good general health determine thorough medical history physical examination , vital sign Clinical diagnosis elevate Blood Pressure define : Having systolic prehypertension measurement systolic BP ( mmHg ) 120139 Diastolic BP ( mmHg ) 90 OR Having systolic Stage 1 hypertension measurement systolic BP ( mmHg ) 140159 Diastolic BP ( mmHg ) 100 Hypertension treatment naïve patient , define patient never treat antihypertensive medication hypertensive treatment period 12 week longer . Willing refrain use antihypertensive treatment , investigational product , include herbal supplement , systemic use steroid , chronic use NSAIDS , antihypertensive agent , betablockers , diuretic , ACE inhibitor , CA channel blocker , Alpha blocker , Central Acting agent vasodilator . Ability comprehend comply procedure Agree commit participate current protocol Provide write informed consent prior study procedure perform ( subject able understand inform consent form document subject require read ) Pregnant and/or lactate woman Patients treatment Benign Prostatic Hyperplasia ( BPH ) Clinically significant history cardiovascular disease ( i. e. PCI , CABG MI ( event occur 12 month ) , atrial fibrillation , frequent PAC , cardiac rhythm disorder , syncope , valve repair/replacement , heart transplantation , PTA , peripheral bypass surgery , endarterectomy , unstable angina , TIA , stroke NYHF category II , II IV heart failure . Patients renal failure , significant kidney renal disease define creatinine level mg/dL Presence condition ( medical , psychological , social , geographical ) , actual anticipate , Investigator feel would restrict limit patient 's successful participation duration study History migraine and/or anxiety , patient unable refrain use beta blocker History sensitivity study medication , component thereof history drug allergy , opinion Investigator Medical Monitor , contraindicate participation . The participant previously randomize study Subjects clinical diagnosis Type I Diabetes Subjects arm circumference 42 cm Any condition would prevent subject participate trial opinion evaluation physician The participant receive investigational product within 30 day prior randomization Prior use product contain B244 Nitrosomonas eutropha Unable lie flat sit 15 minute Concurrent participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>elevate blood pressure</keyword>
</DOC>